With the advent of immune checkpoint inhibitors in recent years, significant progress is achieved in the management of advanced melanoma [1–3].However, liver metastasis remains a clinical challenge and had been demonstrated as an independent predictive factor for reduced response and poor outcome in metastatic melanoma patients receiving intravenous PD-1 blockade immunotherapy. The gene discussed is PDCD1; the disease is metastatic melanoma.